These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 35000806)

  • 21. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
    Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
    Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Underutilization of Mineralocorticoid Antagonists in Patients With Heart Failure With Reduced Ejection Fraction.
    Matsumoto S; Kondo T; Jhund PS; Campbell RT; Swedberg K; van Veldhuisen DJ; Pocock SJ; Pitt B; Zannad F; McMurray JJV
    J Am Coll Cardiol; 2023 Sep; 82(11):1080-1091. PubMed ID: 37642608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association Between Mineralocorticoid Receptor Antagonist Use and Outcome in Myocardial Infarction Patients With Heart Failure.
    Löfman I; Szummer K; Olsson H; Carrero JJ; Lund LH; Jernberg T
    J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 29980521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure.
    Suzuki G; Morita H; Mishima T; Sharov VG; Todor A; Tanhehco EJ; Rudolph AE; McMahon EG; Goldstein S; Sabbah HN
    Circulation; 2002 Dec; 106(23):2967-72. PubMed ID: 12460880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Preiss D; van Veldhuisen DJ; Sattar N; Krum H; Swedberg K; Shi H; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ
    Eur J Heart Fail; 2012 Aug; 14(8):909-15. PubMed ID: 22611047
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Heart failure with systolic dysfunction complicating acute myocardial infarction - differential outcomes but similar eplerenone efficacy by ST-segment or non-ST-segment elevation: A post hoc substudy of the EPHESUS trial.
    Carillo S; Zhang Y; Fay R; Angioi M; Vincent J; Sutradhor SC; Ahmed A; Pitt B; Zannad F
    Arch Cardiovasc Dis; 2014 Mar; 107(3):149-57. PubMed ID: 24630753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure.
    Pitt B; Ahmed A; Love TE; Krum H; Nicolau J; Cardoso JS; Parkhomenko A; Aschermann M; Corbalán R; Solomon H; Shi H; Zannad F
    Hypertension; 2008 Aug; 52(2):271-8. PubMed ID: 18559720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF).
    Cannon JA; Collier TJ; Shen L; Swedberg K; Krum H; Van Veldhuisen DJ; Vincent J; Pocock SJ; Pitt B; Zannad F; McMurray JJ
    Eur J Heart Fail; 2015 Jul; 17(7):707-16. PubMed ID: 26139584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of Mineralocorticoid Receptor Antagonists on the Prognosis of Patients with Ventricular Tachyarrhythmias.
    Schupp T; von Zworowsky M; Reiser L; Abumayyaleh M; Weidner K; Mashayekhi K; Bertsch T; Abba ML; Akin I; Behnes M
    Pharmacology; 2022; 107(1-2):35-45. PubMed ID: 34879385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of evidence of lower 30-day all-cause readmission in Medicare beneficiaries with heart failure and reduced ejection fraction discharged on spironolactone.
    Lam PH; Dooley DJ; Inampudi C; Arundel C; Fonarow GC; Butler J; Wu WC; Blackman MR; Anker MS; Deedwania P; White M; Prabhu SD; Morgan CJ; Love TE; Aronow WS; Allman RM; Ahmed A
    Int J Cardiol; 2017 Jan; 227():462-466. PubMed ID: 27866868
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT.
    Ferreira JP; Rossello X; Eschalier R; McMurray JJV; Pocock S; Girerd N; Rossignol P; Pitt B; Zannad F
    JACC Heart Fail; 2019 Dec; 7(12):1012-1021. PubMed ID: 31779922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Role of eplerenone in the threatment of cardiovascular diseases].
    Málek F
    Vnitr Lek; 2023; 69(E-2):23-25. PubMed ID: 37072263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Effects of Spironolactone and Eplerenone on Left Ventricular Function Using Echocardiography in Symptomatic Patients With New-Onset Systolic Heart Failure: A Comparative Randomised Controlled Trial.
    Nabati M; Tabiban S; Khani A; Yazdani J; Vafainezhad H
    Heart Lung Circ; 2021 Sep; 30(9):1292-1301. PubMed ID: 33744193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review regarding the article 'Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a network meta-analysis of 32 randomized trials'.
    Wang L; Yuan D
    Curr Probl Cardiol; 2024 Aug; 49(8):102644. PubMed ID: 38750993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.